Together, our results suggest a central role for STAT3 and epigenetic changes to drive LGLL pathogenesis, and provide rationale for testing hypomethylating agents in the treatment of LGLL patients resistant to standard therapies. This evidence concerns the gene STAT3 and T-cell large granular lymphocyte leukemia.